These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19285629)

  • 21. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
    Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
    Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation.
    Chen XH; Gao L; Zhang X; Gao L; Zhang C; Kong PY; Liu H; Peng XG; Sun AH; Qi DG; Gong Y; Wang QY
    Blood Cells Mol Dis; 2009; 43(1):98-104. PubMed ID: 19356956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.
    Pérez A; González-Vicent M; Ramirez M; Sevilla J; Madero L; Díaz MA
    Br J Haematol; 2008 Feb; 140(3):340-3. PubMed ID: 18053071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic chimerism induces renal and skin allograft tolerance in DLA-identical dogs.
    Tillson M; Niemeyer GP; Welch JA; Brawner W; Swaim SF; Rynders P; Lenz SD; Dean B; Lothrop CD
    Exp Hematol; 2006 Dec; 34(12):1759-70. PubMed ID: 17157174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant.
    Toh HC; Spitzer TR; Preffer F; Alexander SI; McAfee S; Dombkowski D; Clark JS; Colby C; Saidman S; Sackstein R; Sykes M
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):43-7. PubMed ID: 12607794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
    Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
    Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation.
    Sugita J; Tanaka J; Hashimoto A; Shiratori S; Yasumoto A; Wakasa K; Kikuchi M; Shigematsu A; Miura Y; Tsutsumi Y; Kondo T; Asaka M; Imamura M
    Ann Hematol; 2008 Dec; 87(12):1003-8. PubMed ID: 18636260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
    Grosskreutz C; Scigliano E; Osman K; Isola L
    Transplantation; 2007 Sep; 84(5):598-604. PubMed ID: 17876272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia.
    Ooi J; Takahashi S; Tomonari A; Tsukada N; Konuma T; Kato S; Kasahara S; Sato A; Monma F; Nagamura F; Iseki T; Tojo A; Asano S
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1341-7. PubMed ID: 19041055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal allograft tolerance in DLA-identical and haploidentical dogs after nonmyeloablative conditioning and transient immunosuppression with cyclosporine and mycophenolate mofetil.
    Niemeyer GP; Welch JA; Tillson M; Brawner W; Rynders P; Goodman S; Dufresne M; Dennis J; Lothrop CD
    Transplant Proc; 2005 Dec; 37(10):4579-86. PubMed ID: 16387175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
    Li S; Salgar SK; Kurimoto Y; Yousem S; Pham SM
    J Surg Res; 2008 May; 146(2):289-97. PubMed ID: 18314139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?
    Hari P; Logan B; Drobyski WR
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):743-7. PubMed ID: 15505605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerance and chimerism.
    Kolb HJ; Guenther W; Gyurkocza B; Hoetzl F; Simoes B; Falk C; Schleuning M; Ledderose G
    Transplantation; 2003 May; 75(9 Suppl):26S-31S. PubMed ID: 12819487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.
    Ting DT; Spitzer TR; Chaudhary A; Muzikansky A; Colby C; Power K; McAfee S; Ballen K; Attar E; Saidman SL; Preffer F; Sykes M; Dey BR
    Bone Marrow Transplant; 2008 Sep; 42(5):329-35. PubMed ID: 18587439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.